Safety and Tolerability of Single and Multiple Doses of Neumifil
Status:
Recruiting
Trial end date:
2022-04-15
Target enrollment:
Participant gender:
Summary
This is a Phase 1, single-centre, randomised, placebo-controlled first in human study in
healthy subjects. The study will assess the safety and tolerability of single-ascending (Part
A) and multiple-ascending (Part B) doses of Neumifil, administered intranasally.